TRAVA Review – It Cites the Right Standard

We have spent several of these reviews correcting sellers who call their compounding partners “FDA-approved”. TRAVA cites USP sterility standards instead — which is the accurate thing to say, and a decent proxy for whether anyone at a company understands what they are selling.

It Cites the Right Standard

TRAVA describes its medications as prepared in “state-licensed pharmacies that follow USP safety and sterility standards”, and states plainly that both tirzepatide and semaglutide are compounded and not FDA-approved.

Compare that with what we found elsewhere. Marek Health describes its pharmacies as “FDA-approved”, and MD365 calls its 503B partner an “FDA-approved 503b pharmacy”. The FDA approves drugs, not pharmacies, and it does not review compounded preparations for safety, effectiveness or quality at all. TRAVA reaches for the accurate claim rather than the impressive-sounding one.

This is a small thing that signals a larger one. Getting regulatory vocabulary right is cheap if you know it and impossible to fake consistently if you do not — and in a market where the compounding status is the single most consequential fact, a seller who describes it precisely has earned a little more trust than one who reaches for borrowed authority.

The one thing missing is third-party testing. USP standards describe how a preparation should be made; independent assay confirms what actually ended up in the vial. Curex publishes potency, sterility, pH and endotoxicity testing, which is a step beyond citing the standard. Ask TRAVA whether batch certificates are available.

Near the Bottom of the Market

Compounded semaglutide is quoted as low as $88.65 a month and compounded tirzepatide as low as $178.98, with GLP-1 treatment described as starting at $89 and the consultation included.

Those figures sit at the very bottom of what we have found. Ozari Health publishes $86 for semaglutide and $125 for tirzepatide; TRAVA is within a few dollars on semaglutide and higher on tirzepatide. Against the wider field — where we have reviewed compounded semaglutide at $495 and compounded tirzepatide at $695 — this is a fraction of the going rate.

Including the consultation in the price is meaningful too. A great many services advertise a low medication figure and add a consultation fee, a membership and shipping on top; several we have reviewed charge $99 to $299 just to be assessed. HSA and FSA cards are accepted, and insurance is not required or billed.

Precise Numbers, Loose Qualifier

The prices are quoted to the cent — $88.65 and $178.98 — and prefaced with “as low as”.

This matters for GLP-1s specifically because dose escalation moves the price. Semaglutide is titrated from 0.25 mg toward a maintenance dose up to 2.4 mg, and compounded pricing almost always rises along that path. A floor price describes month one; nothing here describes month six. A separate figure of “starting at $89” also sits alongside the $88.65, which is a trivial inconsistency but not a reassuring one on a page about transparent pricing.

Ask what the price is at a maintenance dose before starting. That single number turns an entry price into an annual budget, and it is the thing a “no hidden fees” claim ought to cover.

No States, No Labs, No Refunds

The intake is a roughly ten-minute online form, reviewed by licensed, board-certified providers before a prescription is issued. Ten minutes is thin for a prescription with real contraindications, though it is notably more than the two-minute intakes we found at Ozari and Curex, and provider review before prescribing is the right sequence.

The gaps are conventional but real. No states served are published, which matters because telehealth prescribing is licensed state by state. No laboratory requirements appear and no BMI criteria are stated. There is no refund policy, no shipping timeline or cost, and the compounding pharmacies are not named.

The absence of a refund policy sits particularly awkwardly against the “no hidden fees” framing — what happens if you stop after two weeks is exactly the kind of thing a transparency claim should answer.

Provider Facts

Pros and Cons

Who It May Be Best For

A good fit if cost is the binding constraint and you want compounded semaglutide at close to the lowest published rate, with the consultation included rather than billed on top.

Ask for the maintenance-dose price before starting. “As low as” describes the cheapest dose, and these medications escalate — the month-six figure is the one that decides affordability.

Confirm your state, since no list is published, and get baseline labs through your own doctor — TRAVA does not require them, and a basic metabolic panel and thyroid check cost less than a month of medication.

Alternatives

Ozari Health is marginally cheaper and publishes a 50-state footprint. Curex publishes third-party batch testing. Emerge Weight Loss bundles everything into one flat figure. Our cheapest GLP-1 programs page ranks the value end.

Limitations of This Review

Based on TRAVA’s own published materials at taketrava.com, checked on 6 September 2026. Prices are the published floor figures and will rise with dose; no ceiling is published, so we cannot state an annual cost. Anything marked not published means we could not find it on the pages we reached. Our description of what USP standards cover and of what the FDA does and does not approve reflects those bodies’ own published positions, not claims by TRAVA. Nothing here is medical advice.

Frequently Asked Questions

Verdict

The point worth carrying beyond this provider: how a company describes its compounding is a usable signal. “USP standards” and “state-licensed” are what a careful operator says; “FDA-approved pharmacy” is what someone says when they want the authority without the accuracy. The vocabulary is free to get right.